scispace - formally typeset
T

Tessa L. Holyoake

Researcher at University of Glasgow

Publications -  273
Citations -  20875

Tessa L. Holyoake is an academic researcher from University of Glasgow. The author has contributed to research in topics: Stem cell & Imatinib mesylate. The author has an hindex of 65, co-authored 272 publications receiving 18780 citations. Previous affiliations of Tessa L. Holyoake include Scottish National Blood Transfusion Service & Western General Hospital.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy

Daniel J. Klionsky, +1287 more
- 01 Apr 2012 - 
TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

Susan M. Graham, +6 more
- 01 Jan 2002 - 
TL;DR: In vitro insensitivity to STI571, in combination with its demonstrated antiproliferative activity, could translate into disease relapse after prolonged therapy despite dramatic short-term responses in vivo.
Journal ArticleDOI

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

Mhairi Copland, +8 more
- 01 Jun 2006 - 
TL;DR: It is confirmed that dasatinib is more effective than IM within the CML stem cell compartment; however, the most primitive quiescent CML cells appear to be inherently resistant to both drugs.
Journal ArticleDOI

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

Camille N. Abboud, +118 more
- 30 May 2013 - 
TL;DR: There is a need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.
Journal ArticleDOI

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.

Cristian Bellodi, +20 more
- 01 May 2009 - 
TL;DR: The authors showed that IM-induced autophagy did not involve c-Abl or Bcl-2 activity, but was associated with ER stress and was suppressed by depletion of intracellular Ca2+, suggesting it is mechanistically nonoverlapping with IMinduced apoptosis.